Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T01358
(Former ID: TTDI01280)
|
|||||
Target Name |
Cell cycle (CC)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Breast cancer [ICD-11: 2C60-2C6Y] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | BZL-101 | Drug Info | Phase 2 | Breast cancer | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | BZL-101 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405. | |||||
REF 2 | ClinicalTrials.gov (NCT00907959) A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.